2006年毕业于中国药科大学与南京大学联合培养的生化药学强化班，2011年博士毕业于中科院上海药物研究所，留所工作后历任助理研究员、副研究员、研究员。

围绕肿瘤表观遗传重塑与微环境异常开展药物研究。利用化学生物学手段对蛋白修饰酶进行靶点发现、药理机制分析、药物开发与药物敏感特征分析。重点关注表观遗传修饰酶之间协同与拮抗的关系，建立了十余个表观遗传修饰酶的药物开发与研究体系。

以第一作者或者通讯作者（含共同）身份发表研究性论文17篇，刊登于Cell、Clin Cancer Res、Cancer Lett、J Med Chem等期刊。申请专利5项，其中PCT 2项，授权1项。

入选2019年国家自然科学基金“优秀青年基金”，2014年中国科学院“青促会”会员，获上海市人才发展资金资助。主持国家自然科学基金项目、国家科技重大专项（子任务）、中科院战略性先导科技专项（子课题）等研究性项目8项。

1、表观遗传修饰酶协作机制

2、靶向组蛋白修饰的化学探针与先导药物研发

3、肿瘤免疫微环境中的表观遗传重塑

2019年 赛诺菲-中国科学院上海生命科学研究院优秀青年人才奖

十篇代表性文章：

1.Xun Huang#, Juan Yan#, Min Zhang#, Yafang Wang#, Yi Chen, Xuhong Fu, Rongrui Wei, Xingling Zheng, Zhiwei Liu, Xiong Zhang, Hong Yang, Binbin Hao, Yanyan Shen, Yi Su, Xiaoji Cong, Min Huang, Minjia Tan*, Jian Ding*, Meiyu Geng*. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-aberrant Solid Tumors. Cell, 2018;175:186-199.

2.Xiaoyang Dai#, Juan Yan#, Xuhong Fu, Qiuming Pan, Danni Sun, Yuan Xu, Jiang Wang, Litong Nie, Linjiang Tong, Aijun Shen, Mingyue Zheng, Min Huang, Minjia Tan, Hong Liu, Xun Huang*, Jian Ding*, Meiyu Geng*. Aspirin Inhibits Cancer Metastasis and Angiogenesis via Targeting Heparanase. Clin Cancer Res, 2017;23(20):6267-6278.

3.Xiong Zhang#, Xingling Zheng#, Hong Yang, Juan Yan, Xuhong Fu, Rongrui Wei, Xiaowei Xu, Zhuqing Zhang, Aisong Yu, Kaixin Zhou, Jian Ding*, Meiyu Geng*, Xun Huang*. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis. Cancer Lett, 2018;431:150-160.

4.Danni Sun#, Hongchun Liu#, Xiaoyang Dai, Xingling Zheng, Juan Yan, Rongrui Wei, Xuhong Fu, Min Huang, Aijun Shen, Xun Huang*, Jian Ding*, Meiyu Geng*. Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition. Cancer Lett, 2017;406:105-115.

5.Zuhao Guo#, Zhuqing Zhang#, Hong Yang, Danyan Cao, Xiaowei Xu, Xingling Zheng, Danqi Chen, Qi Wang, Yanlian Li, Jian Li, Zhiyan Du, Xin Wang, Lin Chen, Jian Ding, Jingkang Shen, Meiyu Geng*, Xun Huang*, Bing Xiong*. Design and Synthesis of Potent, Selective Inhibitors of Protein Arginine Methyltransferase 4 against Acute Myeloid Leukemia. J Med Chem, 2019;62(11):5414-5433.

6.Ruiqi Liu# , Zhuqing Zhang#, Hong Yang, Kaixin Zhou, Meiyu Geng, Weicheng Zhou*, Mingming Zhang*, Xun Huang*, Yingxia Li*. Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors. Eur J Med Chem, 2019;180:171-190.

7.Lidan Sun#, Xun Huang#, Jing Han, Xingguang Cai, Yuxuan Dai, Yingying Chu, Chuandong Wang, Wenlong Huang*, Hai Qian*. Site-specific fatty chain-modified exenatide analogs with balanced glucoregulatory activity and prolonged in vivo activity. Biochem Pharmacol, 2016;110-111:80-91.

8.Xun Huang#, Danni Sun#, Qiuming Pan, Weiwei Wen, Yi Chen, Xianliang Xin, Min Huang, Jian Ding* and Meiyu Geng*. JG6, a novel marine-derived oligosaccharide, suppresses breast cancer metastasis via binding to cofilin. Oncotarget, 2014;5(11):3568-78.

9.Xun Huang#, Qiuming Pan#, Danni Sun, Wei Chen, Aijun Shen, Min Huang, Jian Ding*, Meiyu Geng*. O-GlcNAcylation of Cofilin Promotes Breast Cancer Cell Invasion. J Biol Chem, 2013;288(51):36418-25.

10.Shuai Wang#, Xun Huang#, Danni Sun, Xianliang Xin, Qiuming Pan, Shuying Peng, Zhongjie Liang, Cheng Luo, Yiming Yang, Hualiang Jiang, Min Huang, Wengang Chai, Jian Ding*, Meiyu Geng*. Extensive Crosstalk between O-GlcNAcylation and Phosphorylation Regulates Akt Signaling. PLoS ONE, 2012;7(5): e37427.